NASDAQ:ACOR Acorda Therapeutics - ACOR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.98 +0.01 (+1.03%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.97▼$1.0450-Day Range$0.52▼$1.0052-Week Range$0.26▼$2.29Volume128,148 shsAverage Volume295,533 shsMarket Capitalization$23.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Acorda Therapeutics (NASDAQ:ACOR) StockAcorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.Read More Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACOR Stock News HeadlinesFebruary 2, 2023 | marketwatch.comSpinal Cord Trauma Treatment Market 2023 Latest Research, Top Impacting Factors, Growth Strategies and Forecast to 2028January 31, 2023 | finance.yahoo.comAcorda Therapeutics to Present at Sequire Biotechnology ConferenceFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 30, 2023 | americanbankingnews.comStockNews.com Upgrades Acorda Therapeutics (NASDAQ:ACOR) to "Buy"January 23, 2023 | marketwatch.comMethyl Salicylate Patches Market Register to Growth by 2023-2027 | Global Revenue and Key Dynamics with Industry SegmentsJanuary 17, 2023 | marketwatch.comRepeat Expansion Disorders Treatment Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2029January 5, 2023 | finance.yahoo.comAcorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®December 22, 2022 | finance.yahoo.comAcorda Therapeutics Announces Revised Long-Term Financial GuidanceFebruary 4, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 21, 2022 | msn.comAcorda Therapeutics gets Nasdaq delisting notice, plans to appeal decisionDecember 20, 2022 | finance.yahoo.comAcorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a HearingDecember 9, 2022 | marketwatch.comSpinal Cord Trauma Treatment Market 2023 : Manufacturers Strategies, Share Estimation, Future Demand and Regional Growth Dynamics 2028December 5, 2022 | baystreet.caAcorda Edges up on Making Interest PaymentDecember 5, 2022 | finance.yahoo.comAcorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in CashNovember 19, 2022 | finance.yahoo.comAcorda Therapeutics Third Quarter 2022 Earnings: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)November 11, 2022 | finance.yahoo.comAcorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of StockholdersNovember 9, 2022 | msn.comHow Is The Market Feeling About Acorda Therapeutics?November 1, 2022 | finance.yahoo.comAcorda Therapeutics Reports Third Quarter 2022 Financial ResultsNovember 1, 2022 | proactiveinvestors.comAcorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meetingNovember 1, 2022 | proactiveinvestors.comAcorda Therapeutics shares fly after it provides fresh revenue guidanceOctober 27, 2022 | finance.yahoo.comAcorda Therapeutics Provides Long-Term Business Plan and Financial GuidanceOctober 25, 2022 | finance.yahoo.comAcorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022October 21, 2022 | finance.yahoo.comAcorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.October 20, 2022 | msn.comWhy Ericsson Shares Are Trading Lower? Here Are 56 Stocks Moving In Thursday's Mid-Day SessionOctober 19, 2022 | finance.yahoo.comISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock SplitOctober 18, 2022 | finance.yahoo.comAcorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured DebtOctober 17, 2022 | marketwatch.comAcorda Shares Surge Premarket on Ampyra Arbitration Win >ACORSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ACOR Company Calendar Last Earnings11/09/2021Today2/04/2023Next Earnings (Estimated)3/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACOR CUSIP00484M10 CIK1008848 Webwww.acorda.com Phone(914) 347-4300Fax914-347-4560Employees118Year Founded1995Profitability EPS (Most Recent Fiscal Year)($7.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-103,950,000.00 Net Margins-85.97% Pretax Margin-61.03% Return on Equity-96.44% Return on Assets-25.41% Debt Debt-to-Equity Ratio2.48 Current Ratio1.71 Quick Ratio1.34 Sales & Book Value Annual Sales$129.07 million Price / Sales0.18 Cash FlowN/A Price / Cash FlowN/A Book Value$13.49 per share Price / Book0.07Miscellaneous Outstanding Shares24,280,000Free Float23,768,000Market Cap$23.82 million OptionableOptionable Beta1.43 Social Links Key ExecutivesRonald CohenPresident, Chief Executive Officer & DirectorMichael GesserChief Financial Officer & TreasurerKerry ClemChief Commercial OfficerBurkhard BlankHead-Drug SafetySofia AliSenior VP-Operations & Strategic PlanningKey CompetitorsSAB BiotherapeuticsNASDAQ:SABSCurisNASDAQ:CRISSQZ BiotechnologiesNYSE:SQZFinch Therapeutics GroupNASDAQ:FNCHRubius TherapeuticsNASDAQ:RUBYView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 62,300 shares on 2/2/2023Ownership: 0.000%Renaissance Technologies LLCSold 45,526 shares on 11/14/2022Ownership: 3.525%Ron CohenSold 2,289 sharesTotal: $3,891.30 ($1.70/share)View All Insider TransactionsView All Institutional Transactions ACOR Stock - Frequently Asked Questions How have ACOR shares performed in 2023? Acorda Therapeutics' stock was trading at $0.7667 at the beginning of the year. Since then, ACOR shares have increased by 28.0% and is now trading at $0.9810. View the best growth stocks for 2023 here. When is Acorda Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023. View our ACOR earnings forecast. How were Acorda Therapeutics' earnings last quarter? Acorda Therapeutics, Inc. (NASDAQ:ACOR) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.43) EPS for the quarter, beating analysts' consensus estimates of ($1.56) by $0.13. The biopharmaceutical company earned $31.46 million during the quarter, compared to the consensus estimate of $30.57 million. Acorda Therapeutics had a negative net margin of 85.97% and a negative trailing twelve-month return on equity of 96.44%. When did Acorda Therapeutics' stock split? Acorda Therapeutics's stock reverse split on Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What guidance has Acorda Therapeutics issued on next quarter's earnings? Acorda Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, December, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $116.00 million-$119.70 million, compared to the consensus revenue estimate of $120.51 million. What is Ron Cohen's approval rating as Acorda Therapeutics' CEO? 39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Acorda Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT). What is Acorda Therapeutics' stock symbol? Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR." Who are Acorda Therapeutics' major shareholders? Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Acorda Therapeutics? Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acorda Therapeutics' stock price today? One share of ACOR stock can currently be purchased for approximately $0.98. How much money does Acorda Therapeutics make? Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $23.82 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis. How many employees does Acorda Therapeutics have? The company employs 118 workers across the globe. How can I contact Acorda Therapeutics? Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560. This page (NASDAQ:ACOR) was last updated on 2/4/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.